Joshua Di Vincenzo

MSc researcher / clinical research staff member at the University Health Network and University of Toronto

Data updated

Papers

8 publications

Trials

0 clinical trials

Research Footprint

Joshua Di Vincenzo appears in 8 tracked papers (2021–2023), most studied alongside Ketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Suicidality.

Most-cited paper: Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis (169 citations).

Frequent co-authors: Jonathan Rosenblat, Joseph Vincenzo and Roger McIntyre.

Background & Research

Joshua D. Di Vincenzo appears in the psychiatric ketamine literature as a researcher based at the University Health Network in Toronto and the University of Toronto. ClinicalTrials.gov lists him as a study contact for mood-disorder trials, and PubMed records show him as an author on multiple ketamine-focused reviews and real-world effectiveness studies.

Key Impact

He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.

8

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

20 collaborators· click a node to visit their profile

Full network →

Compounds

Ketamine

Topics

Depressive DisordersTreatment-Resistant Depression (TRD)SuicidalityAnxiety DisordersMajor Depressive Disorder (MDD)Bipolar DisorderPublic Health, Prevention & Behaviour ChangeSafety & Risk ManagementBorderline Personality Disorder (BPD)Personality DisordersNeuroimaging & Brain MeasuresChronic PainImmunology & InflammationAdolescentsOlder AdultsSchizophrenia

Top Collaborators

Affiliations

Institutions, companies, and organisations Joshua Di Vincenzo is associated with.

University of Toronto Mississauga

academic

The Psychedelic Studies Research Program (PSRP) distinguishes itself by adhering strictly to the principles of Open Science, pre-registering their analysis plans, and making their data and protocols freely accessible. A primary focus for the team at the PSRP is the clinical study of microdosing. Led by Dr. Norman Farb, the program conducts double-blind, randomized controlled trials investigating the benefits and drawbacks of microdosing very low doses of psilocybin.

View stakeholder →